Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report

Despite increasing rates of renal replacement therapy, data supporting the safe and effective use of HIV treatment guidelines preferred regimens in people on hemodialysis or peritoneal dialysis is limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a guideline recommended initi...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of STD & AIDS Vol. 34; no. 2; p. 139
Main Authors Partosh, Dor, Sherman, Elizabeth M, Eckardt, Paula A, Unger, Nathan, Montalvo, Sheila
Format Journal Article
LanguageEnglish
Published England 01.02.2023
Subjects
Adenine - therapeutic use
Adult
Anti-HIV Agents - therapeutic use
Drug Combinations
Emtricitabine - therapeutic use
HIV Infections - complications
HIV Infections - drug therapy
Humans
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Peritoneal Dialysis
treatment
AIDS
antiretroviral therapy
antiviral
viral disease
Human immunodeficiency virus viral disease
Online AccessGet more information

Cover

More Information
Summary:Despite increasing rates of renal replacement therapy, data supporting the safe and effective use of HIV treatment guidelines preferred regimens in people on hemodialysis or peritoneal dialysis is limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a guideline recommended initial regimen for most people with HIV with FDA-approval for use in virologically suppressed people receiving chronic hemodialysis; however, the safety and efficacy of BIC/FTC/TAF remains unknown when used in patients on chronic ambulatory peritoneal dialysis (CAPD). We report the first case of BIC/FTC/TAF use in CAPD.
ISSN:1758-1052
DOI:10.1177/09564624221140949